Latest Royalties News

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.

Jupiter Mines Limited reported a modest rise in net profit to $40.1 million for FY2025, supported by strong joint venture earnings and increased marketing fees. The company declared a final dividend as manganese prices stabilized after early-year volatility.

Orion Equities reported a $1.33 million net profit for FY25, down 56% from the prior year, impacted by unrealised losses on key investments and a significant tax benefit reversal. The company’s portfolio remains anchored by stakes in Bentley Capital and Strike Resources.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Core Lithium Ltd has launched a non-underwritten equity raising to secure approximately A$60 million, aiming to advance its Finniss Lithium Project to a final investment decision. The capital raise includes a two-tranche placement and a share purchase plan, supporting operational readiness and strategic funding efforts.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

Caravel Minerals has appointed Primero Group as the EPCM contractor for its Caravel Copper Project, with the Definitive Feasibility Study now fully funded and on track for completion in early 2026.